Insider Transactions in Q1 2025 at Incyte Corp (INCY)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
974
+0.01%
|
-
|
|
Mar 31
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
363
+2.04%
|
$21,780
$60.55 P/Share
|
|
Mar 31
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
358
+1.75%
|
$21,480
$60.55 P/Share
|
|
Mar 25
2025
|
Matteo Trotta EVP, GM, Dermatology US |
SELL
Payment of exercise price or tax liability
|
Direct |
537
-5.13%
|
$33,294
$62.08 P/Share
|
|
Mar 14
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
19,807
-12.52%
|
$1,327,069
$67.8 P/Share
|
|
Mar 04
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
599
-2.26%
|
$41,331
$69.99 P/Share
|
|
Mar 04
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
599
+2.21%
|
$34,742
$58.06 P/Share
|
|
Feb 26
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
14,069
-19.4%
|
$1,041,106
$74.08 P/Share
|
|
Feb 26
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
9,574
+19.34%
|
$555,292
$58.06 P/Share
|
|
Jan 31
2025
|
Lee Heeson EVP, Head of Incyte Intl |
BUY
Grant, award, or other acquisition
|
Direct |
6,331
+16.19%
|
-
|
|
Jan 31
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,552
+11.46%
|
-
|
|
Jan 21
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
429
-0.6%
|
$31,317
$73.47 P/Share
|
|
Jan 21
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,352
-15.57%
|
$889,344
$72.69 P/Share
|
|
Jan 15
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,692
-11.88%
|
$769,824
$72.46 P/Share
|
|
Jan 15
2025
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,672
-3.86%
|
$264,384
$72.46 P/Share
|
|
Jan 15
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
908
-1.26%
|
$65,376
$72.46 P/Share
|
|
Jan 15
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
3,158
-5.59%
|
$227,376
$72.46 P/Share
|
|
Jan 06
2025
|
Mohamed Khairie Issa EVP, Head of US Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
48,671
+50.0%
|
-
|